0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Intravenous or Inhaled Pentamidine for Treating Pneumocystis carinii Pneumonia in AIDS: A Randomized Trial

John E. Conte Jr., MD; David Chernoff, MD; David W. Feigal Jr., MD, MPH; Pat Joseph, MD; Charles McDonald, MD; and Jeffrey A. Golden, MD
[+] Article and Author Information

Grant Support: In part by the Division of Research Resources, R79, U.S. Public Health Service; the University wide Task Force on AIDS Award (R87SF087); and Lypho Med, Inc.

Requests for Reprints: John E. Conte, Jr., MD, Department of Medicine, Medical Center at the University of California, 505 Parnassus Avenue, San Francisco, CA 94143-0208.

Current Author Addresses: Drs. Conte, Chernoff, and Golden: Department of Medicine, Medical Center at the University of California, San Francisco, CA 94143-0208.

Dr. Feigal: UCSD Medical Center, San Diego, CA 92103.

Dr. Joseph: Adult Immunology and AIDS Clinic, Peralta Hospital, Hawthorne Avenue and Webster Street, Oakland, CA 94609.

Dr. McDonald: Pacific Presbyterian Medical Center, 2333 Buchanan, San Francisco, CA 94115


© 1990 American College of PhysiciansAmerican College of Physicians


Ann Intern Med. 1990;113(3):203-209. doi:10.7326/0003-4819-113-3-203
Text Size: A A A

Objective: To evaluate the efficacy and toxicity of aerosolized pentamidine and of reduced-dose intravenous pentamidine for the treatment of mild to moderate Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome (AIDS).

Design: Randomized open study with serial pulmonary function testing and measurement of pentamidine concentrations in plasma and bronchoalveolar lavage fluid.

Patients: Of 44 men and 1 woman with a mild to moderate first episode of P. carinii pneumonia (PaO2 ≥ 7.3 kPa [55 mm Hg]), 23 received aerosolized pentamidine and 22, intravenous pentamidine.

Interventions: Pentamidine isethionate, 600 mg by inhalation using a Respirgard II nebulizer (Marquest Medical Products, Inc., Englewood, Colorado) or 3 mg/kg body weight intravenously, administered once daily for 2 to 3 weeks.

Measurements and Main Results: The planned 60-patient study was stopped after 45 patients had been enrolled. The rates (aerosolized compared with intravenous pentamidine) of initial failure, early recrudescence of symptoms, and relapse were 12% and 19% (difference, 7%; 99% confidence interval [CI], -23% to 37%; P = 0.67), 35% and 0% (difference, 35%; CI, 13% to 58%; P = 0.02), and 24% and 0% (difference, 24%; CI, 4% to 49%; P = 0.03). The rates (aerosolized compared with intravenous pentamidine) of major toxicity were 0% (0 of 17 patients) and 10% (2 of 21 patients) (difference 10%; CI, -1% to 29%; P = 0.24). The mean (±SD) pentamidine concentration in bronchoalveolar lavage fluid for patients receiving aerosolized pentamidine was 96.6 ± 65.1 ng/mL compared with 14.4 ± 17.7 ng/mL for patients receiving intravenous treatment. Trough concentrations of pentamidine in plasma increased from 0 to 25.4 ± 16.4, 56.5 ± 26.1, and 61.1 ± 56.0 ng/mL at the end of weeks 1, 2, and 3 of intravenous therapy, respectively.

Conclusions: The data suggest that reduced-dose intravenous pentamidine was more effective than aerosolized pentamidine for treating mild to moderate P. carinii pneumonia. Systemic absorption during aerosolized therapy was minimal; daily doses of intravenous pentamidine resulted in increased accumulation of pentamidine in plasma.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)